This clinical trial is focused on studying a type of blood cancer called Acute Myeloid Leukemia (AML). The study is comparing two different treatments for patients with newly diagnosed AML that is considered to be of intermediate or high risk based on genetic factors. One treatment being tested is a medication called CPX-351, which is a combination of two drugs, cytarabine and daunorubicin, delivered in a special form called liposomal. The other treatment is a more traditional intensive chemotherapy approach using a combination of idarubicin and cytarabine.
The purpose of the study is to see if CPX-351 can help more patients achieve a deep remission, which means the cancer is significantly reduced or undetectable, compared to the traditional chemotherapy. Patients in the study will be randomly assigned to receive either CPX-351 or the traditional chemotherapy. The study will monitor the patients’ response to the treatment, focusing on how well the cancer is controlled and how the patients’ bodies handle the treatment. The study will also look at the quality of life of the patients during the treatment.
Throughout the study, patients will receive their assigned treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will last for several months, with regular check-ups and assessments to track the progress of the treatment. The goal is to gather information that could help improve treatment options for people with AML in the future.
France 
